Castle Biosciences, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Castle Biosciences, Inc. (Nasdaq: CSTL) develops and commercializes molecular diagnostic tests that guide patient care for dermatologic cancers, Barrett's esophagus, uveal melanoma, and related conditions; its core portfolio includes DecisionDx-Melanoma, a 31-gene expression profile (GEP) test predicting metastasis risk, sentinel lymph node positivity, and recurrence in invasive cutaneous melanoma; TissueCypher, a spatial-omics risk stratification test predicting progression to high-grade dysplasia or esophageal cancer in Barrett's esophagus patients with non-dysplastic, indefinite, or low-grade dysplasia; DecisionDx-SCC, a 40-GEP test assessing metastasis risk, adjuvant radiation therapy benefit, and local recurrence in high-risk cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test aiding differentiation of melanocytic lesions; DecisionDx-UM, a GEP test with PRAME refinement predicting metastasis in uveal melanoma; and AdvanceAD-Tx, a 487-GEP test guiding systemic treatment selection for moderate-to-severe atopic dermatitis patients aged 12 and older. The company, founded in 2008 and headquartered in Friendswood, Texas, operates laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, serving clinicians in dermatology, gastroenterology, and oncology primarily in the United States. Recent developments include the May 2025 acquisition of Capsulomics, Inc. (d/b/a Previse), adding methylation-based technology to enhance gastrointestinal offerings and enable multiomics approaches for Barrett's esophagus and non-endoscopic sampling; a June 2025 collaboration and license agreement with SciBase Holding AB leveraging electrical impedance spectroscopy for an atopic dermatitis flare prediction test; discontinuation of the IDgenetix pharmacogenomic test for mental health conditions in May 2025; FDA Breakthrough Device designation for DecisionDx-Melanoma in July 2025; and the launch of AdvanceAD-Tx to address biologic treatment decisions in atopic dermatitis.
Company News
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
Castle Biosciences to Open New Laboratory Facility in Scottsdale
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
SciBase receives additional order from Castle Biosciences, advancing the collaboration
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences Q2 Earnings Call Highlights
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)